North America Lung Transplant Therapeutics Market to 2032
Overview
The North America Lung Transplant Therapeutics Market is expected to reach a 130.75 USD Million by 2032 and is projected to grow at a CAGR of 7.54% from 2025 to 2032.
Revenue, 2024 (USD Million)
82.87
Forecast, 2032 (USD Million)
130.75
CAGR, 2024 - 2032
7.54%
Report Coverage
North America
North America Lung Transplant Therapeutics Market 2018-2032 USD Million
North America Lung Transplant Therapeutics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 82.87 USD Million
- Projected Market Size (2032): 130.75 USD Million
- CAGR (2025-2032): 7.54%
Key Findings of North America Lung Transplant Therapeutics Market
- The North America Lung Transplant Therapeutics Market was valued at 82.87 USD Million in 2024.
- The North America Lung Transplant Therapeutics Market is likely to grow at a CAGR of 7.54% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Cadaveric Lung Transplant in Type Segment accounted for the largest share of the market with a revenue of 79.56 USD Million
- The fastest growing segment Cystic Fibrosis in Indication Segment grew Fastest with a CAGR of 10.71% during the forecast period from 2024 to 2032.
North America Lung Transplant Therapeutics Market Scope
North America Lung Transplant Therapeutics Market Segmentation & Scope
End Users
- Others
- Specialty Centers
- Transplant Centers
- Hospital
Patient Demographics
- Pediatric
- Geriatric
- Adults
Product
- Others
- Tissue Product
- Organ Preservation Products
- Immunosuppressant Drugs
Indication
- Others
- Septic Lung disease
- Sarcoidosis
- Emphysema
- Primary Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Interstitial pulmonary fibrosis
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Fibrosis
- Cystic Fibrosis
Type
- Living Lung Transplant
- Cadaveric Lung Transplant
Technique
- Heart-Lung Transplant
- Bilateral Lung Transplant (BLT)
- Double Lung Transplant
- Single-Lung Transplant (SLT)
North America Lung Transplant Therapeutics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 82.87 USD Million |
| Market Value in 2032 | 130.75 USD Million |
| CAGR (2025-2032) | 7.54% |
| Historic Data | 2016-2023 |
| Market Segments Covered | End Users,Patient Demographics,Product,Indication,Type,Technique |
Regional Insights:
-
Leading Market (2024-2032): North America, leading in terms of revenue 82.87 USD Million in 2024
- Key Country: U.S., leading in terms of revenue with value of 73.25 USD Million in 2024.
Segments and Scope
-
North America Lung Transplant Therapeutics Market to 2032, By End Users
- Hospital is the largest segment in North America Lung Transplant Therapeutics Market to 2032 with a revenue of 57.27 USD Million in the year 2024.
- Hospital is the Fastest growing segment in North America Lung Transplant Therapeutics Market to 2032 with a Growth rate of 7.81 % in forecast period 2025-2032.
-
North America Lung Transplant Therapeutics Market to 2032, By Patient Demographics
- Adults is the largest segment in North America Lung Transplant Therapeutics Market to 2032 with a revenue of 46.91 USD Million in the year 2024.
- Adults is the Fastest growing segment in North America Lung Transplant Therapeutics Market to 2032 with a Growth rate of 7.97 % in forecast period 2025-2032.
-
North America Lung Transplant Therapeutics Market to 2032, By Product
- Immunosuppressant Drugs is the largest segment in North America Lung Transplant Therapeutics Market to 2032 with a revenue of 64.06 USD Million in the year 2024.
- Immunosuppressant Drugs is the Fastest growing segment in North America Lung Transplant Therapeutics Market to 2032 with a Growth rate of 7.79 % in forecast period 2025-2032.
-
North America Lung Transplant Therapeutics Market to 2032, By Indication
- Cystic Fibrosis is the largest segment in North America Lung Transplant Therapeutics Market to 2032 with a revenue of 22.25 USD Million in the year 2024.
- Cystic Fibrosis is the Fastest growing segment in North America Lung Transplant Therapeutics Market to 2032 with a Growth rate of 10.71 % in forecast period 2025-2032.
-
North America Lung Transplant Therapeutics Market to 2032, By Type
- Cadaveric Lung Transplant is the largest segment in North America Lung Transplant Therapeutics Market to 2032 with a revenue of 79.56 USD Million in the year 2024.
- Cadaveric Lung Transplant is the Fastest growing segment in North America Lung Transplant Therapeutics Market to 2032 with a Growth rate of 7.67 % in forecast period 2025-2032.
-
North America Lung Transplant Therapeutics Market to 2032, By Technique
- Single-Lung Transplant (SLT) is the largest segment in North America Lung Transplant Therapeutics Market to 2032 with a revenue of 48.91 USD Million in the year 2024.
- Single-Lung Transplant (SLT) is the Fastest growing segment in North America Lung Transplant Therapeutics Market to 2032 with a Growth rate of 8.15 % in forecast period 2025-2032.
North America Lung Transplant Therapeutics Market Company Share Analysis
| Company Name |
|
||
| Viatris Inc. | |||
| ose-immuno | |||
| Panacea Biotec | |||
| Paragonix Technologies, Inc | |||
| NOVARTIS AG | |||
North America Lung Transplant Therapeutics Market Geographical Sales Distribution, 2018-2032 USD Million
North America Lung Transplant Therapeutics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The North America Lung Transplant Therapeutics Market is segmented based on Segmentation End Users,Patient Demographics,Product,Indication,Type,Technique.
North America Lung Transplant Therapeutics Market was valued at USD 82.87(Revenue in USD Million) in 2022.
North America Lung Transplant Therapeutics Market is projected to grow at a CAGR of 7.54% during the forecast period of 2024 to 2032.
The Cadaveric Lung Transplant segment is expected to dominate the North America Lung Transplant Therapeutics Market, holding a largest market share of 79.56 USD Million in 2024
North America Lung Transplant Therapeutics Market Scope
North America Lung Transplant Therapeutics Market Segmentation & Scope
End Users
- Others
- Specialty Centers
- Transplant Centers
- Hospital
Patient Demographics
- Pediatric
- Geriatric
- Adults
Product
- Others
- Tissue Product
- Organ Preservation Products
- Immunosuppressant Drugs
Indication
- Others
- Septic Lung disease
- Sarcoidosis
- Emphysema
- Primary Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Interstitial pulmonary fibrosis
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Fibrosis
- Cystic Fibrosis
Type
- Living Lung Transplant
- Cadaveric Lung Transplant
Technique
- Heart-Lung Transplant
- Bilateral Lung Transplant (BLT)
- Double Lung Transplant
- Single-Lung Transplant (SLT)
Frequently Asked Questions
The North America Lung Transplant Therapeutics Market is segmented based on Segmentation End Users,Patient Demographics,Product,Indication,Type,Technique.
North America Lung Transplant Therapeutics Market was valued at USD 82.87(Revenue in USD Million) in 2022.
North America Lung Transplant Therapeutics Market is projected to grow at a CAGR of 7.54% during the forecast period of 2024 to 2032.
The estimated market value of the North America Lung Transplant Therapeutics Market for final year is USD 130.75 (USD Million).
North America Lung Transplant Therapeutics Market Company Profiling
Frequently Asked Questions
The North America Lung Transplant Therapeutics Market is segmented based on Segmentation End Users,Patient Demographics,Product,Indication,Type,Technique.
North America Lung Transplant Therapeutics Market was valued at USD 82.87(Revenue in USD Million) in 2022.
North America Lung Transplant Therapeutics Market is projected to grow at a CAGR of 7.54% during the forecast period of 2024 to 2032.
The estimated market value of the North America Lung Transplant Therapeutics Market for final year is USD 130.75 (USD Million).
CHOOSE LICENCE TYPE
- 4200.00
- 3500.00
- 2000.00
- 5500.00
- 8500.00
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.